Italia Markets open in 1 hr 54 mins

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
51,60+19,46 (+60,55%)
Alla chiusura: 04:57PM BST
Schermo intero
Chiusura precedente32,14
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno30,69 - 31,05
Intervallo di 52 settimane30,69 - 31,05
Media VolumeN/D
Beta (5 anni mensile)0,88
Rapporto PE (ttm)12,33
EPS (ttm)4,18
Prossima data utili27 apr 2022 - 02 mag 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

    GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conju

  • GlobeNewswire

    Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

    GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate were published in The Lancet Infectious Diseases. The article, Safety and immunogenicity of PXVX0317, an aluminum hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised

  • GlobeNewswire

    Emergent BioSolutions to Participate in Investor Conferences

    GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 ConferenceJune 2, 2022 NYSE Healthcare & Technology Virtual Investor Access DayJune 8, 2022 East Coast IDEAS ConferenceJune 22, 2022Pre-recorded presentation will be accessible beginning at 6:00 am ET